Evidence to Date: Ranibizumab and Its Potential in the Treatment of Retinopathy of Prematurity

Eye and Brain - New Zealand
doi 10.2147/eb.s189684
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Comparison of Intravitreal Ranibizumab and Bevacizumab Treatment for Retinopathy of Prematurity

Arquivos Brasileiros de Oftalmologia
MedicineOphthalmology
2015English

Profile of Buparlisib and Its Potential in the Treatment of Breast Cancer: Evidence to Date [Corrigendum]

Breast Cancer: Targets and Therapy
Oncology
2018English

Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2017English

Retinopathy of Prematurity: Causes, Prevention and Treatment

British Journal of Midwifery
MidwiferyMaternity
2016English

Spotlight on Siponimod and Its Potential in the Treatment of Secondary Progressive Multiple Sclerosis: The Evidence to Date

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

Ranibizumab in the Treatment of Chronic Central Serous Chorio Retinopathy

Advances in Ophthalmology & Visual System
2017English

Revised Indications for the Treatment of Retinopathy of Prematurity

Archives of Ophthalmology
2003English

Current Update on Retinopathy of Prematurity: Screening and Treatment

Current Opinion in Pediatrics
Child HealthPediatricsPerinatology
2011English

Diode Laser Treatment of Posterior Retinopathy of Prematurity

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy